Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

DISEASE CHARACTERISTICS:

• Histologically confirmed malignant mesothelioma of any of the following subtypes:
• Epithelial
• Sarcomatoid
• Mixed
• Any site of origin of malignant mesothelioma allowed including, but not limited to, any of the following:
• Pleura
• Peritoneum
• Pericardium
• Tunica vaginalis
• Pathology blocks or slides from a core surgical biopsy must be available
• Not amenable to curative surgery
• Measurable disease, defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques (CT scan , MRI, or x-ray) or as ≥ 10 mm with spiral CT scan
• Patients with pleural rind only disease must have at least one level with one rind measurement ≥ 1.5 cm
• Lesions that are considered nonmeasurable include the following:
• Bone lesions
• Leptomeningeal disease
• Ascites
• Pleural/pericardial effusion
• Lymphangitis cutis/pulmonis
• Abdominal masses that are not confirmed and followed by imaging techniques
• Cystic lesions
• Prior treatment with one and only one systemic chemotherapy regimen, which must have included pemetrexed disodium required
• Treatment may have been with pemetrexed disodium alone or in combination with any other agent
• No symptomatic pleural effusions, unless the patient undergoes a therapeutic thoracentesis
• Patients with pleural effusions who have had a pleurodesis are eligible
• No known brain metastases
• May be registered on CALGB-150707 companion study

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1
• Granulocytes ≥ 1,500/μL
• Platelet count ≥ 100,000/μL
• Total bilirubin ≤ 2 x upper limit of normal (ULN)
• AST (SGOT) ≤ 2.5 x ULN
• Creatinine clearance ≥ 60 mL/min
• INR < 1.5
• PTT < 40 seconds
• QTc < 450 msec
• Not pregnant or nursing
• Fertile patients must use effective contraception
• No significant cardiac disease, including any of the following:
• New York Heart Association (NYHA) class III-IV congestive heart failure (CHF)
• Unstable angina
• Myocardial infarction or ventricular tachyarrhythmia within 6 months of study entry
• Ejection fraction less than institutional normal (in patients with a history of CHF or currently with NYHA class I or II CHF)
• Prolonged QTc > 450 msec (Fridericia correction)
• Major conduction abnormality, unless a cardiac pacemaker is present
• Hypokalemia or hypomagnesemia that cannot be corrected
• No history of significant bleeding disorder unrelated to cancer, including any of the following:
• Congenital bleeding disorder (e.g., von Willebrand disease)
• Acquired bleeding disorder within the past year (e.g., acquired anti-factor VIII antibodies)
• Ongoing or recent (≤ 3 months) significant GI bleeding or hemoptysis
• No requirement for supplemental oxygen (i.e., pulse oximetry < 89% at rest)

PRIOR CONCURRENT THERAPY:

• At least 4 weeks since prior pemetrexed disodium-containing chemotherapy
• At least 4 weeks since prior major surgery
• At least 4 weeks since prior radiation therapy
• Measurable disease must be outside the radiation port
• Prior intracavitary cytotoxic or sclerosing therapy (including bleomycin) allowed
• Intrapleural cytotoxic chemotherapy will not be considered systemic chemotherapy
• At least 7 days since prior and no concurrent antithrombotic or anti-platelet agents, including any of the following:
• Aspirin or aspirin-containing combinations
• Clopidogrel
• Dipyridamole
• Tirofiban
• Epoprostenol
• Eptifibatide
• Cilostazol
• Abciximab
• Ticlopidine
• Warfarin
• Low-dose warfarin for prophylaxis to prevent catheter thrombosis allowed
• Heparin or low molecular weight heparin
• Heparin for IV line flush allowed
• At least 7 days since prior and no concurrent use of the following drugs:
• Itraconazole
• Ketoconazole (at doses > 200 mg/day)
• Miconazole
• Voriconazole
• Telithromycin
• Primidone
• Rifabutin
• Rifampin
• St. John's wort
• Carbamazepine
• Oxcarbazepine
• Rifapentine
• Phenobarbital
• Phenytoin
• Quinidine
• Procainamide
• Disopyramide
• Amiodarone
• Sotalol
• Ibutilide
• Dofetilide
• Erythromycin
• Clarithromycin
• Chlorpromazine
• Haloperidol
• Mesoridazine
• Thioridazine
• Pimozide
• Bepridil
• Droperidol
• Halofantrine
• Levomethadyl
• Sparfloxacin
• No concurrent H2 blockers or proton pump inhibitors
• No bisphosphonate therapy during the first 8 weeks of study treatment
• No concurrent hormones or other chemotherapeutic agents except for steroids administered for dasatinib-related pleural effusion or hormones administered for non-disease-related conditions (e.g., insulin for diabetes)
• No concurrent palliative radiation therapy